Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Non-Current Liabilities: 2021-2025

Historic Other Non-Current Liabilities for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $2.4 million.

  • SAB Biotherapeutics' Other Non-Current Liabilities fell 41.67% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 41.67%. This contributed to the annual value of $6.4 million for FY2024, which is 45.74% down from last year.
  • SAB Biotherapeutics' Other Non-Current Liabilities amounted to $2.4 million in Q3 2025, which was up 20.26% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Other Non-Current Liabilities registered a high of $11.8 million during Q4 2023, and its lowest value of $238,344 during Q1 2023.
  • Over the past 3 years, SAB Biotherapeutics' median Other Non-Current Liabilities value was $2.4 million (recorded in 2025), while the average stood at $3.6 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Other Non-Current Liabilities tumbled by 97.01% in 2022, and later spiked by 3,568.79% in 2023.
  • SAB Biotherapeutics' Other Non-Current Liabilities (Quarterly) stood at $10.7 million in 2021, then tumbled by 97.01% to $320,930 in 2022, then surged by 3,568.79% to $11.8 million in 2023, then plummeted by 45.74% to $6.4 million in 2024, then slumped by 41.67% to $2.4 million in 2025.
  • Its Other Non-Current Liabilities was $2.4 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.4 million in Q1 2025.